Imagine if you could test a medicine on a tiny version of your own brain in a lab before taking it yourself. Instead of spending months guessing which antidepressant works, a simple blood sample creates a personalized model to find the right match. It takes the guesswork out of mental health treatment, like a tailor-made suit for your brain chemistry.
Physicians currently use a trial-and-error method to treat depression, testing drugs for 4-6 weeks each. This leads to high disability rates, increased suicide risk, and massive healthcare costs.
A 3-pillared AI decision support tool and a physician platform interface that uses blood samples to predict the best antidepressant for a patient.
If you are a clinic dealing with the 63% of depression patients who fail their first treatment—this project developed a decision support tool that matches patients with the right drug immediately. This removes the 4-6 week trial-and-error wait time per medication.
If you are a payer dealing with high costs of chronic depression—this project developed a screening platform that can reduce healthcare costs by 40%. This leads to potential savings of up to 6,000 per patient per year.
If you are a pharma company dealing with high drug failure rates in clinical trials—this project developed a brain-in-a-dish screening platform. It uses patient-specific models to predict how different antidepressants will perform based on genetics and neurobiology.
Based on available project data, it can reduce depression-related healthcare costs by 40%, with savings up to 6,000 per patient per year.
The company has developed an initial user interface for the physician platform and is expanding clinical trials in the US and Israel to gather effectiveness data.
GenetikaPlus has secured CE-IVD, HIPAA, and GDPR compliance levels, along with QMS/GLP implementation.
It aims to reduce hospitalizations by 89% and emergency-room visits by 71% by eliminating the trial-and-error process that currently takes 4-6 weeks per drug.
Based on available project data, specific licensing terms are not mentioned, but the project is developing a physician platform for market launch.
The project is led by a single SME, GenetikaPlus Ltd from Israel. With a 100% industry ratio and no university or research partners, the project is lean and focused on commercialization, utilizing a total EU contribution of EUR 2,499,000 to move from research to market launch.
Contact GenetikaPlus Ltd in Israel for licensing and partnership opportunities.
Contact us to explore integration of this CDSS into your clinical workflow.
